FLT3 inhibition has been a goal of acute myeloid leukemia (AML) therapy since FLT3
mutations were discovered to have a role in AML. Several FLT3 inhibitors have been …

Acute myeloid leukemia (AML) is a highly aggressive illness distinguished by the
accumulation of abnormal hematopoietic precursors in both the bone marrow and peripheral …

Mutations in the FMS-like tyrosine kinase 3 (FLT3) gene arise in 25-30% of all acute myeloid
leukemia (AML) patients. These mutations lead to constitutive activation of the protein …

The fms-like tyrosine kinase 3 (FLT3) plays an important role in both normal and malignant
hematopoiesis. Activating mutations in the FLT3 receptor can be detected in approximately …

FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in AML. Thirty percent
of patients with acute myeloid leukemia (AML) harbor activating mutations in FLT3, either …

The optimal role for targeting FLT3 may depend on multimodality therapy and will likely
require hematopoietic transplant. The incorporation of ABL kinase inhibitors into acute …

Fms-like tyrosine kinase-3 (FLT3) mutations occur in approximately 30% of acute myeloid
leukemia (AML) cases, suggesting FLT3 as an attractive target for AML treatment. Early …

Introduction: Activating mutations of the FMS-like tyrosine kinase 3 (FLT3) gene occur at
high frequency in acute myeloid leukemia (AML), being detected in> 30% of patients at …

Mutations in the fms-like tyrosine kinase 3 (FLT3) gene are detected in approximately one-
third of patients with newly diagnosed acute myeloid leukemia (AML). These consist of the …

Internal tandem duplications and tyrosine kinase mutations in the fms-like tyrosine kinase 3
(FLT3) receptor can occur in acute myeloid leukemia (AML) and portend a poor prognosis …